Home » Stocks » INAB

IN8bio, Inc. (INAB)

IN8bio was planning to go public, but the IPO has been postponed.
Stock Price: $15.00 - $17.00
Current IPO price range
Market Cap 310.89M
Revenue (ttm) n/a
Net Income (ttm) -8.23M
Shares Out 19.43M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News
TheStreet - 2 months ago

IN8bio was founded to advance a pipeline of treatment options for glioblastoma [GBM] and acute leukemia using 'allogeneic, autologous and genetically modified gamma-delta T cells.

NASDAQ - 3 months ago

IN8bio, a Phase 1 biotech developing allogeneic T cell therapies for cancer and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering.

SEC - 3 months ago

IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

About INAB

IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct... [Read more...]

Industry
Biotechnology
IPO Date
Postponed
CEO
William Ho
Employees
7
Stock Exchange
NYSE
Ticker Symbol
INAB
Full Company Profile